Nadja Mannowetz,
Co-Founder & CSO $300,000 / 2 years Awarded 2021 |
Nadja Mannowetz, PhDYourChoice Therapeutics
Berkeley, CA About
Dr. Nadja Mannowetz is the Chief Scientific Officer of YourChoice Therapeutics, who is working on a novel inhibitor of the male contraceptive target Retinoic Acid Receptor Alpha. With a background in sperm biology, Nadja co-founded YourChoice Therapeutics in 2018 with the goal of developing novel non-hormonal contraceptive products. Our Grant
MCI is supporting YourChoice’s work in developing a reversible male contraceptive drug, YCT-529, which prevents the production of new sperm. MCI has both a grant and a program-related investment with YourChoice, which seeks to take any returns and feed them directly back into the contraceptive development community. MCI’s support will facilitate work that progresses YCT-529 towards first-in-human studies and eventual FDA approval. |
MCI Grantee: YourChoice Therapeutics
Publications
Noman, M. A. A., Kyzer, J. L., Chung, S. S. W., Wolgemuth, D. J., & Georg, G. I. (2020). Retinoic acid receptor antagonists for male contraception: current status†. Biology of reproduction, 103(2), 390–399. https://doi.org/10.1093/biolre/ioaa122
Noman, M. A. A., Kyzer, J. L., Chung, S. S. W., Wolgemuth, D. J., & Georg, G. I. (2020). Retinoic acid receptor antagonists for male contraception: current status†. Biology of reproduction, 103(2), 390–399. https://doi.org/10.1093/biolre/ioaa122
